ArticleHepatology forum2021
The prevalence of metabolic-associated fatty liver disease in the Turkish population: A multicenter study.
Article in Hepatology forum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.Hepatology international · 2025Guideline
- Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.Hepatology international · 2024Pooled it
- Comparative Diagnostic Performance of Metabolic Scoring Indices for Ultrasonographic Hepatic Steatosis: Development and Validation of a Novel Composite Score in 1204 Consecutive Patients.Journal of clinical medicine · 2026Article
- Glycogen metabolic dysfunction in T2DM with MASLD: linking α-hydroxybutyrate to GYS2 downregulation.Frontiers in nutrition · 2026Article
- TASL practice guidance for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD).Hepatology forum · 2026Article
- Discriminating prevalent type 2 diabetes among community-dwelling older adults with metabolic dysfunction-associated steatotic liver disease: a comparative analysis of 12 insulin resistance surrogates.Frontiers in endocrinology · 2026Article
- Prevalence of MASLD and fibrosis in Turkey: Results from a multicenter study of at-risk populations.PloS one · 2026Observational
- Hepatic steatosis is associated with HBsAg seroclearance in patients with chronic hepatitis B virus infection but it is also associated with disease progression.Hepatology forum · 2026Article
- Prevalence of MASLD and Fibrosis Risk in Turkish Adults with Cardiometabolic Risk Factors: A Nationwide Multicenter Study (DAHUDER MASLD Study).Journal of clinical medicine · 2025Article
- A prospective study on the role of non-invasive tests in the evaluation of diabetes mellitus associated steatotic liver disease.Scientific reports · 2025Article
- Effects of Intermittent Fasting on Liver Steatosis and Fibrosis, Serum FGF-21 and Autophagy Markers in Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized Controlled Trial.Life (Basel, Switzerland) · 2025Article
- Non-invasive tests fail to ensure therapeutic precision for resmetirom in MASLD.Hepatology forum · 2025Article
- Microplastics and nanoplastics: Emerging drivers of liver damage and metabolic dysfunction.Hepatology forum · 2025Review
- Effects of rifaximin in fructose-induced steatohepatitis in rats.Hepatology forum · 2025Article
- Non-invasive tests for resmetirom treatment fail to accurately define the target population: Evidence from a biopsy-proven MASLD cohort.Hepatology forum · 2025Article
- Article
- Metabolic Dysfunction Associated Fatty Liver Disease in Long-Term Cholecystectomy Patients: A Cross-Sectional Study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Article
- Assessing hepatic steatosis by magnetic resonance in potential living liver donorsDiagnostic and interventional radiology (Ankara, Turkey) · 2024Article
- MAFLD as part of systemic metabolic dysregulation.Hepatology international · 2024Review
- Changing Trends in the Etiology of Cirrhosis in Türkiye: A Multicenter Nationwide Study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: The objective of the present study was to investigate the prevalence of metabolic-associated fatty liver disease (MAFLD) in patients with dyspepsia. Materials and Methods: A total of 909 consecutive patients who presented with dyspepsia at 8 tertiary care centers in Turkey between March 2019 and December 2019 were included. Results: The median age was 47 years. Among them, 30.3% of the patients were obese, 18.8% had type 2 diabetes mellitus (T2DM), 35.1% had metabolic syndrome, 84.8% had dyslipidemia, and 23.9% had hypertension. The prevalence of MAFLD was 45.5%. Among the patients with MAFLD, the prevalence of obesity, T2DM, metabolic syndrome, dyslipidemia, and hypertension was 43.3%, 24.9%, 52.5%, 92.3%, and 31.9%, respectively. MAFLD was significantly associated with all of the metabolic comorbidities (p<0.001). The median Fibrosis-4 Index score of the MAFLD patients was 0.88 (range: 0.1-9.5). Of note, 53 patients with hepatic steatosis did not meet the MAFLD criteria. Conclusion: The results of the present study indicated that there was a significantly high prevalence of MAFLD observed in daily clinical practice in Turkey. Early diagnosis and prevention efforts should be implemented to reduce disease progression, and a region-based strategy is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.